Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

59.70 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 59.70
Bid (Size) 59.00 (100)
Ask (Size) 60.60 (100)
Prev. Close 59.70
Today's Range 59.70 - 59.70
52wk Range 14.79 - 62.32
Shares Outstanding 41,151,111
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% ↗
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally ↗
Focused on cancer therapies, this Boulder-based biotech reported significant insider selling amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+284.2%
+284.2%
1 Month
+19.4%
+19.4%
3 Month
+44.9%
+44.9%
6 Month
+114.6%
+114.6%
1 Year
+210.6%
+210.6%

More News

Read More
News headline image
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
From Equity Insider
Via GlobeNewswire
S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours ↗
Via Stocktwits
Topics Government Stocks
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗
Via Stocktwits
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Resemble AI Unleashes Chatterbox Turbo: A New Era for Open-Source Real-Time Voice AI
Via TokenRing AI
Topics Artificial Intelligence Fraud Hacking
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Enliven Posts Loss Beat and Cash Surge ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗
Via Stocktwits

Frequently Asked Questions

Is Enliven Therapeutics, Inc. - Common Stock publicly traded?
Yes, Enliven Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Enliven Therapeutics, Inc. - Common Stock trade on?
Enliven Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enliven Therapeutics, Inc. - Common Stock?
The ticker symbol for Enliven Therapeutics, Inc. - Common Stock is ELVN on the Nasdaq Stock Market
What is the current price of Enliven Therapeutics, Inc. - Common Stock?
The current price of Enliven Therapeutics, Inc. - Common Stock is 59.70
When was Enliven Therapeutics, Inc. - Common Stock last traded?
The last trade of Enliven Therapeutics, Inc. - Common Stock was at 08/05/26 04:00 PM ET
What is the market capitalization of Enliven Therapeutics, Inc. - Common Stock?
The market capitalization of Enliven Therapeutics, Inc. - Common Stock is 2.46B
How many shares of Enliven Therapeutics, Inc. - Common Stock are outstanding?
Enliven Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.